BLTE
Belite Bio, Inc NASDAQ Listed Apr 29, 2022$163.05
+1.48%
vs $160.67
Mkt Cap $6.5B
52w Low $60.00
73.6% of range
52w High $200.00
50d MA $149.57
200d MA $151.89
P/E (TTM)
—
EV/EBITDA
—
P/B
7.1x
Debt/Equity
0.0x
ROE
-10.1%
P/FCF
-147.1x
RSI (14)
60.70
ATR (14)
$5.67
Beta
-1.22
50d MA
$149.57
200d MA
$151.89
Avg Volume
177.7K
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
5820 Oberlin Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 20, 2026 | AMC | -0.63 | -0.34 | +46.5% | 143.36 | +1.0% | +0.6% | -4.8% | +3.4% | +0.1% | +4.2% | — |
| May 13, 2026 | BMO | — | — | — | 155.54 | -3.6% | -1.3% | -2.3% | -4.6% | -0.1% | -2.2% | — |
| May 12, 2026 | BMO | — | — | — | 151.97 | -0.6% | +2.3% | -1.3% | -2.3% | -4.6% | -0.1% | — |
| Mar 2, 2026 | AMC | -0.56 | -0.38 | +32.1% | 177.58 | +0.0% | -5.5% | +5.9% | -2.9% | +0.4% | +3.4% | — |
| Nov 10, 2025 | AMC | -0.53 | -0.65 | -22.6% | 117.34 | -2.0% | -9.9% | +4.8% | +1.4% | +3.8% | +0.2% | — |
| Aug 11, 2025 | AMC | -0.47 | -0.50 | -6.4% | 69.50 | +0.0% | +4.6% | -1.6% | -3.6% | -3.4% | -2.5% | — |
| May 13, 2025 | AMC | -0.36 | -0.45 | -25.0% | 60.89 | +0.0% | +1.2% | +8.9% | -4.0% | +0.9% | -0.3% | — |
| Mar 17, 2025 | AMC | -0.30 | -0.32 | -6.7% | 67.81 | +0.3% | +0.8% | -1.0% | +0.1% | -0.7% | -0.5% | — |
| Nov 12, 2024 | AMC | -0.30 | -0.28 | +6.7% | 81.15 | +0.1% | +1.3% | +1.7% | -1.0% | -0.1% | -0.5% | — |
| Aug 9, 2024 | AMC | -0.28 | -0.31 | -10.7% | 49.48 | -4.3% | -1.9% | +3.7% | -0.9% | +0.0% | +0.1% | — |
| May 13, 2024 | AMC | -0.34 | -0.27 | +20.6% | 41.69 | -0.8% | +0.7% | +1.1% | -0.2% | +6.1% | +0.4% | — |
| Mar 11, 2024 | AMC | -0.36 | -0.25 | +30.6% | 44.60 | +1.1% | -12.5% | -2.6% | -0.6% | +1.7% | +6.5% | — |
| Nov 13, 2023 | AMC | -0.31 | -0.40 | -29.0% | 39.30 | -2.0% | -3.6% | -2.3% | +0.5% | +0.0% | +2.7% | — |
| Aug 8, 2023 | AMC | -0.24 | -0.26 | -8.3% | 22.54 | +0.9% | +2.3% | +6.2% | -4.2% | -1.6% | -4.0% | — |
| May 10, 2023 | BMO | -0.20 | -0.33 | -65.0% | 26.22 | +2.6% | +2.3% | -4.7% | -8.0% | -3.1% | -1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $165.23 | $168.90 | +2.2% | +1.3% | -1.8% | -1.9% | +1.1% | -2.7% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $172.76 | $176.18 | +2.0% | +0.2% | -0.7% | -1.8% | -6.3% | +4.7% |
| Mar 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $177.58 | $177.60 | +0.0% | -5.5% | +5.9% | -2.9% | +0.4% | +3.4% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $177.58 | $177.60 | +0.0% | -5.5% | +5.9% | -2.9% | +0.4% | +3.4% |
| Mar 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $177.58 | $177.60 | +0.0% | -5.5% | +5.9% | -2.9% | +0.4% | +3.4% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $167.34 | $167.09 | -0.1% | -1.0% | +2.0% | -0.0% | +2.6% | +8.1% |
| Dec 2 | Mizuho | Upgrade | Neutral → Outperform | — | $154.02 | $160.43 | +4.2% | -2.1% | +0.6% | -0.3% | -0.8% | -0.1% |
| Dec 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $137.44 | $153.50 | +11.7% | +12.1% | -2.1% | +0.6% | -0.3% | -0.8% |
| Oct 31 | Benchmark | Maintains | Buy → Buy | — | $98.10 | $98.85 | +0.8% | +8.0% | +6.1% | -1.2% | +1.2% | -0.6% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.48 | $69.60 | +0.2% | -3.9% | +0.1% | +9.1% | +0.3% | -4.2% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.81 | $57.99 | +2.1% | +4.7% | -1.4% | +2.5% | +6.7% | -3.3% |
| May 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $61.60 | $62.50 | +1.5% | +8.9% | -4.0% | +0.9% | -0.3% | +3.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.60 | $62.50 | +1.5% | +8.9% | -4.0% | +0.9% | -0.3% | +3.8% |
| Mar 26 | Benchmark | Maintains | Buy → Buy | — | $64.50 | $66.58 | +3.2% | +1.1% | +2.5% | -0.2% | -0.7% | -1.8% |
| Mar 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $67.81 | $68.03 | +0.3% | +0.8% | -1.0% | +0.1% | -0.7% | -0.5% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.81 | $68.03 | +0.3% | +0.8% | -1.0% | +0.1% | -0.7% | -0.5% |
| Jan 21 | Benchmark | Maintains | Buy → Buy | — | $56.21 | $58.24 | +3.6% | +3.6% | +1.2% | -1.2% | +2.1% | -3.5% |
| Nov 15 | Maxim Group | Maintains | Buy → Buy | — | $83.66 | $83.60 | -0.1% | -1.0% | -0.1% | -0.5% | +0.2% | -0.1% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $81.15 | $81.20 | +0.1% | +1.3% | +1.7% | -1.0% | -0.1% | -0.5% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.69 | $48.67 | -0.0% | +0.0% | +0.2% | -0.1% | -0.5% | -0.4% |
| Aug 13 | Benchmark | Maintains | Buy → Buy | — | $48.55 | $49.04 | +1.0% | +3.7% | -0.9% | +0.0% | +0.1% | -0.1% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.55 | $49.04 | +1.0% | +3.7% | -0.9% | +0.0% | +0.1% | -0.1% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.98 | $49.80 | -0.4% | +0.2% | -0.3% | -0.7% | +0.1% | -1.5% |
| May 16 | Benchmark | Maintains | Buy → Buy | — | $42.45 | $42.42 | -0.1% | -0.2% | +6.1% | +0.4% | +0.6% | -0.9% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.00 | $42.00 | +0.0% | +1.1% | -0.2% | +6.1% | +0.4% | +0.6% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.77 | $43.26 | -1.2% | +0.4% | -0.5% | -0.6% | -8.2% | -3.9% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.04 | $38.01 | -2.6% | -2.6% | -0.6% | +1.7% | +6.5% | +8.9% |
| Dec 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.89 | $45.50 | -0.8% | +0.3% | -0.3% | -0.3% | -6.5% | -8.6% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.88 | $37.50 | -1.0% | -2.3% | +0.5% | +0.0% | +2.7% | -1.1% |
| Nov 7 | Benchmark | Maintains | Buy → Buy | — | $39.23 | $39.00 | -0.6% | +2.2% | -3.5% | +0.8% | +0.9% | -0.1% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.03 | $39.20 | +0.4% | +0.5% | +2.2% | -3.5% | +0.8% | +0.9% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.06 | $22.90 | -0.7% | +6.2% | -4.2% | -1.6% | -4.0% | +0.1% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.20 | $18.00 | -1.1% | -1.6% | +4.0% | +10.4% | +17.3% | -3.7% |
| Jul 25 | Benchmark | Maintains | Buy → Buy | — | $18.20 | $18.00 | -1.1% | -1.6% | +4.0% | +10.4% | +17.3% | -3.7% |
| Jun 20 | Benchmark | Maintains | Buy → Buy | — | $13.23 | $13.23 | +0.0% | +6.9% | -3.8% | -9.8% | -8.9% | +19.6% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.15 | $17.14 | -0.1% | -9.6% | -2.6% | +0.3% | -2.3% | +1.6% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.51 | $28.70 | +0.7% | +5.2% | -2.9% | -1.7% | +1.3% | +1.2% |
| Apr 4 | Benchmark | Maintains | Buy → Buy | — | $28.51 | $28.70 | +0.7% | +5.2% | -2.9% | -1.7% | +1.3% | +1.2% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.27 | $32.31 | -2.9% | -1.1% | +1.7% | -4.8% | +0.8% | +3.1% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.56 | $32.12 | +1.8% | +5.4% | -1.1% | +1.7% | -4.8% | +0.8% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.60 | $35.13 | +4.6% | +0.0% | -0.3% | -10.4% | -1.7% | +2.9% |
| Jul 1 | Benchmark | Maintains | Buy → Buy | — | $31.14 | $32.00 | +2.8% | +21.0% | +16.7% | -6.6% | +1.0% | +3.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 1,199 | $146.24 | $175K | 15,096 | -1.35% | +3.98% |
| Jun 18, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 4,861 | $145.43 | $707K | 16,295 | -1.35% | +3.98% |
| Jun 18, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 3,748 | $144.66 | $542K | 21,156 | -1.35% | +3.98% |
| Jun 18, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 96 | $143.90 | $14K | 24,904 | -1.35% | +3.98% |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 1,035 | $145.02 | $150K | 25,000 | -1.50% | -0.62% |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 1,897 | $143.55 | $272K | 26,035 | -1.50% | -0.62% |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 450 | $142.20 | $64K | 27,932 | -1.50% | -0.62% |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 100 | $141.83 | $14K | 28,382 | -1.50% | -0.62% |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 540 | $140.58 | $76K | 28,482 | -1.50% | -0.62% |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 3,140 | $139.57 | $438K | 29,022 | -1.50% | -0.62% |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 784 | $138.18 | $108K | 32,162 | -1.50% | -0.62% |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 2,054 | $137.61 | $283K | 32,946 | -1.50% | -0.62% |
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 100 | $155.97 | $16K | 766 | -0.72% | -2.33% |
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 240 | $154.41 | $37K | 866 | -0.72% | -2.33% |
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 128 | $153.42 | $20K | 1,106 | -0.72% | -2.33% |
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 424 | $152.67 | $65K | 1,234 | -0.72% | -2.33% |
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 8 | $151.57 | $1K | 1,658 | -0.72% | -2.33% |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 68 | $158.11 | $11K | 1,666 | -0.13% | -1.30% |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 155 | $157.29 | $24K | 1,734 | -0.13% | -1.30% |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 121 | $156.53 | $19K | 1,889 | -0.13% | -1.30% |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 173 | $155.48 | $27K | 2,010 | -0.13% | -1.30% |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 363 | $154.44 | $56K | 2,183 | -0.13% | -1.30% |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 120 | $153.92 | $18K | 2,546 | -0.13% | -1.30% |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 172 | $157.49 | $27K | 2,666 | +1.19% | +2.35% |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 235 | $156.57 | $37K | 2,838 | +1.19% | +2.35% |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 325 | $155.21 | $50K | 3,073 | +1.19% | +2.35% |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 236 | $154.24 | $36K | 3,398 | +1.19% | +2.35% |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 32 | $153.50 | $5K | 3,634 | +1.19% | +2.35% |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 23 | $160.00 | $4K | 3,666 | -0.08% | -1.88% |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 38 | $159.08 | $6K | 3,689 | -0.08% | -1.88% |
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ubs Group Ag | 768,359 | $123M | Added | Mar 2026 |
| 2 | Rtw Investments, Lp | 715,332 | $114M | — | Mar 2026 |
| 3 | Millennium Management | 570,088 | $91M | Added | Mar 2026 |
| 4 | Deerfield Management Company, L.p. | 304,013 | $48M | Added | Mar 2026 |
| 5 | Duquesne Family Office | 106,100 | $17M | New | Mar 2026 |
| 6 | Mpm Bioimpact Llc | 88,045 | $14M | — | Mar 2026 |
| 7 | Morgan Stanley | 56,026 | $9M | Added | Dec 2025 |
| 8 | Renaissance Technologies Llc | 52,000 | $8M | New | Mar 2026 |
| 9 | Longaeva Partners L.p. | 33,492 | $5M | New | Mar 2026 |
| 10 | Bnp Paribas Financial Markets | 32,525 | $5M | Added | Mar 2026 |
| 11 | Jane Street Group, Llc | 32,318 | $5M | New | Dec 2025 |
| 12 | Adar1 Capital Management, Llc | 26,880 | $4M | New | Mar 2026 |
| 13 | Bank Of Montreal /can/ | 15,981 | $3M | Added | Mar 2026 |
| 14 | Verdad Advisers, Lp | 13,813 | $2M | New | Mar 2026 |
| 15 | Hrt Financial Lp | 10,922 | $2M | Added | Mar 2026 |
| 16 | Barclays Plc | 6,822 | $1M | Added | Mar 2026 |
| 17 | Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 6,004 | $957K | Added | Mar 2026 |
| 18 | Amundi | 4,210 | $671K | New | Mar 2026 |
| 19 | Bank Of America Corp /de/ | 3,778 | $602K | Added | Mar 2026 |
| 20 | Yeomans Consulting Group, Inc. | 2,399 | $384K | New | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 8
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Morgan Stanley Discovery Portfolio | 15,913 | $3M | Mar 2026 |
| 2 | Fidelity Nasdaq Composite Index Fund | 6,727 | $1M | Feb 2026 |
| 3 | Fidelity Nasdaq Composite Index ETF | 3,697 | $704K | Feb 2026 |
| 4 | Select Biotechnology Portfolio | 3,100 | $447K | May 2026 |
| 5 | Virtus LifeSci Biotech Clinical Trials ETF | 1,993 | $337K | Jan 2026 |
| 6 | ActivePassive International Equity ETF | 991 | $189K | Feb 2026 |
| 7 | ULTRACHINA PROFUND | 1,003 | $170K | Jan 2026 |
| 8 | ALGER SMALL CAP GROWTH INSTITUTIONAL FUND | 259 | $44K | Jan 2026 |
Valuation
Market Cap
$6.54B
Enterprise Value
$4.98B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.72x
P/B
7.10x
P/S
—
P/FCF
-147.13x
EV/EBITDA
—
Shares Out
33.5M
Financials (TTM)
Revenue
$0
Net Income
-$90.3M
EBITDA
-$95.6M
Free Cash Flow
-$37.2M
Op Cash Flow
-$37.0M
EPS Basic
$-2.31
EPS Diluted
$-2.55
EPS Forward
$-2.18
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$780.6M
Total Liab.
$10.1M
Total Equity
$770.5M
Cash
$492.4M
LT Debt
$0
Book Value/Sh
$22.97
Debt/Equity
0.00x
Current Ratio
50.02
Quick Ratio
50.02
Returns & Growth
ROE
-10.1%
ROA
-9.9%
ROIC
-10.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
-95.8%
Price Returns
2W
+6.3%
1M
+7.1%
3M
+5.3%
6M
-13.2%
12M
+133.3%
Technicals
52W High
$200.00
52W Low
$60.00
50d MA
$149.57
200d MA
$151.89
RSI (14)
60.70
ATR (14)
$5.67
Beta
-1.22
Avg Volume
178K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$203.00
High
$223.00
Low
$187.00
Median
$200.00
Data updated apr 26, 2026 9:54am
· Source: financialmodelingprep.com